drugset / Trial / NCT01536431
Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes
Phase 1/2
Completed
27 enrolled
Cardiff University
Diabetes Vaccine Development Centre · collabJuvenile Diabetes Research Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to address the safety issue of whether, in patients with newly-diagnosed diabetes who still make some insulin, proinsulin peptide therapy adversely affects the rate of damage to the insulin making cells.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | PROINSULIN HUMAN | Peptide | 10 ug | — |